This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process. Prime...

A female-presenting person speaks at a legislative building, wearing a green blazer and glasses. George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing Alex Cook...

References 1. U.S. Food and Drug Administration. Application number 761381: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Drugs@FDA. Accessed February 6, 2026....

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

Effective Date: July 1, 2026 Introduction, scope, and purpose: Prime Therapeutics LLC and all of its operating units and subsidiaries (“Prime,” “we,” “our”) understands that the privacy of your...

Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

Managed Markets Insight & Technology (MMIT)

Home Newsroom Custom Content Publications High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus...